首页> 外文OA文献 >Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer

【2h】

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer

机译：更新的疗效分析，包括橡树的次要人口结果：患有先前治疗的晚期非小细胞肺癌患者的atezolizumab与多西紫杉醇的随机期III研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Louis Fehrenbacher; Joachim von Pawel; Keunchil Park; Achim Rittmeyer; David R. Gandara; Santiago Ponce Aix; Ji-Youn Han; Shirish M. Gadgeel; Toyoaki Hida; Diego L. Cortinovis; Manuel Cobo; Dariusz M. Kowalski; Filippo De Marinis; Mayank Gandhi; Bradford Danner; Christina Matheny; Marcin Kowanetz; Pei He; Federico Felizzi; Hina Patel; Alan Sandler; Marcus Ballinger; Fabrice Barlesi;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 国产多西紫杉醇治疗晚期非小细胞肺癌的随机对照临床研究 [J] . 曹烨, 王志强, 郭颖, 癌症（英文版） . 2006,第008期
2. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer [J] . Louis Fehrenbacher, Joachim von Pawel, Keunchil Park, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第8期

机译：更新的疗效分析，包括橡树的次要人口结果：患有先前治疗的晚期非小细胞肺癌患者的atezolizumab与多西紫杉醇的随机期III研究
3. Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study [J] . von Pawel J., Bordoni R., Satouchi M., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：用atezolizumab治疗的晚期非小细胞肺癌患者的长期存活与多元紫杉醇：随机期III橡树研究的结果
4. Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non–Small-cell Lung Cancer [J] . Rodolfo Bordoni, Fortunato Ciardiello, Joachim von Pawel, Clinical lung cancer . 2018,第5期

机译：橡木的患者报告的结果：高级非小细胞肺癌中atezolizumab与多西紫杉醇的III期研究
5. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
6. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
7. Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel [O] . David Gandara, Martin Reck, Denis Moro-Sibilot, 2021

机译：非小细胞肺癌的快速进展：随机期III橡树研究的结果评估二线atezolizumab与多西紫杉醇
8. Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non–Small-cell Lung Cancer [O] . Rodolfo Bordoni, Fortunato Ciardiello, Joachim von Pawel, 2018

机译：橡木中的患者报告的结果：在先进的非小细胞肺癌中对atezolizumab与多西紫杉醇的III期研究

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer

著录项

引文网络

相似文献

相关主题

期刊订阅